Dr. Patrick Grierson
Claim this profileWashington University School of Medicine
Expert in Stomach Cancer
Studies Colorectal Cancer
19 reported clinical trials
43 drugs studied
Area of expertise
1Stomach Cancer
Global LeaderStage IV
Stage III
HER2 negative
2Colorectal Cancer
Stage IV
Stage III
Mismatch Repair Deficiency positive
Affiliated Hospitals
Clinical Trials Patrick Grierson is currently running
A2B530 CAR T Therapy
for Solid Cancers
This trial tests A2B530, a treatment using modified immune cells from the patient, in adults with hard-to-treat cancers like colorectal, pancreatic, and lung cancer. The treatment aims to target and kill cancer cells while protecting healthy cells.
Recruiting1 award Phase 1 & 27 criteria
Nivolumab + Standard Treatment
for Stomach and Esophageal Cancer
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria
More about Patrick Grierson
Clinical Trial Related1 year of experience running clinical trials · Led 19 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Patrick Grierson has experience with
- Leucovorin
- Fluorouracil
- Nivolumab
- Oxaliplatin
- Pembrolizumab
- Trastuzumab
Breakdown of trials Patrick Grierson has run
Stomach Cancer
Colorectal Cancer
Pancreatic Cancer
Esophageal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Patrick Grierson specialize in?
Patrick Grierson focuses on Stomach Cancer and Colorectal Cancer. In particular, much of their work with Stomach Cancer has involved Stage IV patients, or patients who are Stage III.
Is Patrick Grierson currently recruiting for clinical trials?
Yes, Patrick Grierson is currently recruiting for 11 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Patrick Grierson has studied deeply?
Yes, Patrick Grierson has studied treatments such as Leucovorin, Fluorouracil, Nivolumab.
What is the best way to schedule an appointment with Patrick Grierson?
Apply for one of the trials that Patrick Grierson is conducting.
What is the office address of Patrick Grierson?
The office of Patrick Grierson is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.